Drug Profile
Research programme: prostaglandin D2 synthase inhibitors - sanofi-aventis
Alternative Names: SAR-102608Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-asthma in France (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in France (PO)
- 22 Apr 2008 Preclinical trials in Allergic asthma in France (PO)